Colitis-induced bone loss is gender dependent and associated with increased inflammation

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1586-1597

  Irwin, Regina ^a   Lee, Taehyung ^a   Young, Vincent B ^b,c   Parameswaran, Narayanan ^a   McCabe, Laura R ^a,d,e  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Infectious Diseases Division   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d St John Hospital and Medical Center   (United States)

^e Biomedical Imaging Research Center   (United States)

Author keywords

Bone; Colitis; Gender; Inflammation; Intestine; Osteoblast

Indexed keywords

INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; BONE STRUCTURE; COLITIS; ENTERITIS; FEMALE; FEMUR; GASTROINTESTINAL TRACT; HELICOBACTER HEPATICUS; HELICOBACTER INFECTION; IMMUNOPATHOLOGY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL; TRABECULAR BONE; VERTEBRA;

ANIMALS; BLOTTING, WESTERN; BONE DENSITY; BONE DISEASES; COLITIS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER HEPATICUS; HELICOBACTER INFECTIONS; INFLAMMATION; INTERLEUKIN-10; INTESTINES; MALE; MICE; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX FACTORS;

EID: 84884573253     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318289e17b     Document Type: Article

References (63)

1. Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res. 2004;19:1961-1968.
2. Sylvester FA, Davis PM, Wyzga N, et al. Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr. 2006;148: 461-466.
3. Semeao EJ, Jawad AF, Zemel BS, et al. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis. 1999;5:161-166.
4. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998; 114:902-911.
5. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:42-50.
6. Sylvester FA. IBD and skeletal health: children are not small adults! Inflamm Bowel Dis. 2005;11:1020-1023.
7. Semeao EJ, Stallings VA, Peck SN, et al. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology. 1997;112: 1710-1713.
8. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
9. Bartram SA, Peaston RT, Rawlings DJ, et al. Multifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol. 2006;12:5680-5686.
10. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233.
11. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93: 1483-1490.
12. van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl. 2006;(243):59-64.
13. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
14. Siffledeen JS, Siminoski K, Steinhart H, et al. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol. 2003;17: 473-478.
15. Siffledeen JS, Fedorak RN, Siminoski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3:122-132.
16. Sentongo TA, Semaeo EJ, Stettler N, et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr. 2002; 76:1077-1081.
17. Vaisman N, Dotan I, Halack A, et al. Malabsorption is a major contributor to underweight in Crohn's disease patients in remission. Nutrition. 2006; 22:855-859.
18. Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics. 2006; 118:1950-1961.
19. Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol. 2004;99:2178-2185.
20. Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn's disease: exercise as a potential countermeasure. Inflamm Bowel Dis. 2005;11: 1108-1118.21.
21. Paganelli M, Albanese C, Borrelli O, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:416-423.
22. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756-1767.
23. Armour KE, Van THRJ, Grabowski PS, et al. Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res. 1999;14:2137-2142.
24. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut. 2000;46:176-181.
25. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6:82-88.
26. Sakellariou GT, Moschos J, Berberidis C, et al. Bone density in young males with recently diagnosed inflammatory bowel disease. Joint Bone Spine. 2006;73:725-728.
27. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031-2035.
28. Miheller P, Muzes G, Zagoni T, et al. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis. 2006;24: 201-206.
29. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci. 2006;1068:543-556.
30. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253-261.
31. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
32. Morrissey PJ, Charrier K. Induction of wasting disease in SCID mice by the transfer of normal CD4+/CD45RBhi T cells and the regulation of this autoreactivity by CD4+/CD45RBlo T cells. Res Immunol. 1994;145:357-362.
33. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224-5231.
34. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev. 2001;14:59-97.
35. On SL, Hynes S, Wadstrom T. Extragastric Helicobacter species. Helicobacter. 2002;7(Suppl 1):63-67.
36. Fox JG. The non-H. pylori helicobacters: their expanding role in gastrointestinal and systemic diseases. Gut. 2002;50:273-283.
37. Chin E, Dangler CA, Fox JG, et al. Helicobacter hepaticus infection triggers inflammatory bowel disease in T cell receptor alpha/beta mutant mice. Comp Med. 2000;50:586-594.
38. Erdman S, Fox JG, Dangler CA, et al. Typhlocolitis in NF-kappa B-deficient mice. J Immunol. 2001;166:1443-1447.
39. Cahill RJ, Foltz CJ, Fox JG, et al. Inflammatory bowel disease: an immunitymediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect Immun. 1997;65:3126-3131.
40. Burich A, Hershberg R, Waggie K, et al. Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2001;281:G764-G778.
41. Kuehl CJ, Wood HD, Marsh TL, et al. Colonization of the cecal mucosa by Helicobacter hepaticus impacts the diversity of the indigenous microbiota. Infect Immun. 2005;73:6952-6961.
42. Fox JG, Ge Z, Whary MT, et al. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. Mucosal Immunol. 2011;4:22-30.
43. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med. 2000;247:63-70.
44. Young VB, Knox KA, Pratt JS, et al. In vitro and in vivo characterization of Helicobacter hepaticus cytolethal distending toxin mutants. Infect Immun. 2004;72:2521-2527.
45. Bleich A, Mahler M, Most C, et al. Refined histopathologic scoring system improves power to detect colitis QTL in mice. Mamm Genome. 2004; 15:865-871.
46. Pratt JS, Sachen KL, Wood HD, et al. Modulation of host immune responses by the cytolethal distending toxin of Helicobacter hepaticus. Infect Immun. 2006;74:4496-4504.
47. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
48. Harris L, Senagore P, Young VB, et al. Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1020-G1029.
49. Patial S, Shahi S, Saini Y, et al. G-protein coupled receptor kinase 5 mediates lipopolysaccharide-induced NFkappaB activation in primary macrophages and modulates inflammation in vivo in mice. J Cell Physiol. 2011;226:1323-1333.
50. Ananthakrishnan AN, McGinley EL, Binion DG, et al. Fracture-associated hospitalizations in patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:176-182.
51. Hamdani G, Gabet Y, Rachmilewitz D, et al. Dextran sodium sulfateinduced colitis causes rapid bone loss in mice. Bone. 2008;43:945-950.
52. Dresner-Pollak R, Gelb N, Rachmilewitz D, et al. Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. Gastroenterology. 2004;127:792-801.
53. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:42-50.
54. Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15:1267-1273.
55. Roth LS, Chande N, Ponich T, et al. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol. 2010;16:232-236.
56. Lee GJ, Kappelman MD, Boyle B, et al. Role of sex in the treatment and clinical outcomes of pediatric patients with inflammatory bowel disease. J Pediatric Gastroenterol Nutr. 2012;5:701-706.
57. Blumenstein I, Herrmann E, Filmann N, et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis. 2011;5:203-210.
58. McCaskey SJ, Rondini EA, Clinthorne JF, et al. Increased presence of effector lymphocytes during Helicobacter hepaticus-induced colitis. World J Gastroenterol. 2012;18:1459-1469.
59. Biswas A, Liu YJ, Hao L, et al. Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum. Proc Natl Acad Sci USA. 2010;107:14739-14744.
60. Buchler G, Wos-Oxley ML, Smoczek A, et al. Strain-specific colitis susceptibility in IL10-deficient mice depends on complex gut microbiota-host interactions. Inflamm Bowel Dis. 2012;18:943-954.
61. Livingston RS, Myles MH, Livingston BA, et al. Sex influence on chronic intestinal inflammation in Helicobacter hepaticus-infected A/JCr mice. Comp Med. 2004;54:301-308.
62. Okoli AS, Raftery MJ, Mendz GL. Effects of human and porcine bile on the proteome of Helicobacter hepaticus. Proteome Sci. 2012;10:27.
63. Kullberg MC, Rothfuchs AG, Jankovic D, et al. Helicobacter hepaticusinduced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect Immun. 2001;69:4232-4241.